The test can detect patients eligible for treatment with GlaxoSmithKline’s (GSK) anti-PD1 immunotherapy Jemperli. Credit: Annett_Klingner from Pixabay.

The US Food and Drug Administration (FDA) has granted approval to Roche’s VENTANA MMR RxDx Panel as a companion diagnostic (CDx) to identify advanced or recurrent endometrial cancer patients.

The panel is a qualitative immunohistochemistry test indicated for analysing mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) in formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue by light microscopy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MMR is a molecular mechanism that works to rectify some errors that can spontaneously happen during DNA replication.

This test can detect patients eligible for treatment with GlaxoSmithKline’s (GSK) anti-PD1 immunotherapy Jemperli (dostarlimab-gxly).

The FDA approved Jemperli based on its biologics license application (BLA) for endometrial cancer last week.

Roche noted that this panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with Jemperli.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche diagnostics CEO Thomas Schinecker said: “We are excited to launch this companion diagnostic test with GSK to help recurrent or advanced endometrial cancer patients with limited treatment options.

“This test provides clinicians with an effective tool to identify patients best suited for treatment with GSK’s Jemperli, providing a new therapeutic option for women with MMR-deficient endometrial cancer whose disease progresses on or following initial chemotherapy treatment.”

The partnership between Roche and GSK signifies a crucial step towards a customised healthcare strategy that can aid in detecting patients who could benefit from a specific treatment.

This CDx will offer clinicians a standardised testing option that utilises a comprehensive panel of DNA MMR biomarkers tested by immunohistochemistry.

Jemperli is indicated for treating mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer patients who have progressed on or have received prior platinum-containing regimen treatment.

MMR deficiency is the most common endometrial cancer and there exist fewer treatment options for women whose disease advances on or after first-line therapy.